First-generation immune checkpoint inhibitors (ICIs) targeting cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) and programed cell death protein 1 (PD-1) or its ligand PD-L1 have become the most potent and durable cancer immunotherapy for patients with many cancer types in various disease settings [5]. This evidence concerns the gene CD274 and cancer.